Last updated: July 5, 2026
Purdue Pharma L.P. v. Amneal Pharmaceuticals LLC (D. Del.) Litigation Summary and Patent/Exclusivity Implications for Generics
Purdue Pharma L.P. sued Amneal Pharmaceuticals LLC in the District of Delaware under Hatch-Waxman for patent infringement tied to Purdue’s opioids and their FDA products, including Paragraph IV-related claims. The case is docketed as 1:15-cv-01152-RGA-SR. Court activity in this matter drove the typical settlement-and-entry pathway in the generic opioid market, shaping when and how Amneal could launch carved-out strengths/forms and which asserted patents were resolved.
What is Purdue Pharma L.P. v. Amneal Pharmaceuticals LLC 1:15-cv-01152-RGA-SR about?
Answer: The action is a Hatch-Waxman patent infringement suit brought by Purdue Pharma L.P. against Amneal Pharmaceuticals LLC in the District of Delaware alleging that Amneal’s ANDA-linked product infringed Purdue’s Orange Book-listed patents, with the dispute framed through the Paragraph IV mechanism.
Core parties
- Plaintiff: Purdue Pharma L.P.
- Defendant: Amneal Pharmaceuticals LLC
- Court/Division: District of Delaware
- Judge: RGA (Richard G. Andrews)
- Magistrate: SR
Procedural posture (what the docket reflects at a high level)
- File is consistent with ANDA litigation where Purdue asserts that Amneal submitted a filing seeking marketing approval during the patent term.
- The “Paragraph IV” framing is the standard Hatch-Waxman hook: Purdue asserts infringement of Orange Book patents and seeks injunctive relief and damages.
Impact zone for business decisions: The practical stakes are generic launch timing and product scope (strengths, dosage forms, and routes) rather than lab-scale infringement design-around, because ANDA products are constrained by FDA’s bioequivalence requirements.
What patents did Purdue assert against Amneal in 1:15-cv-01152-RGA-SR?
Answer: The litigation asserts Orange Book-listed patents covering Purdue’s opioid product(s) and at least one of the asserted claims ties to Amneal’s ANDA Paragraph IV certifications.
How to interpret “what patents” in this docket category
In ANDA litigations, Purdue typically selects a subset of Orange Book patents:
- Composition-of-matter style claims (active ingredient, prodrug, or protected chemical entities where applicable)
- Formulation and controlled-release patents (coating, matrix, excipients, microstructure, or manufacturing controls)
- Method-of-use claims (dosage regimen or therapeutic use claims)
- Manufacturing/process patents (steps and parameters that are easier to distinguish through design-around)
Business relevance
The patent set determines:
- Whether Amneal can launch “at-risk” if an injunction is denied or stays expire
- Whether the parties settle with carve-outs (launch one strength first, delay another)
- Whether post-grant or reexamination/ITC pressure is brought to bear
Constraint: A patent-by-patent list cannot be reproduced accurately from the case caption alone; the docket must be mapped to the complaint and claim chart entries.
What is the procedural timeline for Purdue v. Amneal in 1:15-cv-01152-RGA-SR?
Answer: The case follows the typical Hatch-Waxman cadence: complaint filing in 2015, motions practice on pleading sufficiency and infringement/invalidity, and resolution through judicial rulings and/or settlement-driven dismissal that defines launch conditions.
Key dates that matter commercially
In this docket type, decision nodes for a competitor are:
- Filing date (triggers 30-month stay if the ANDA is filed within the relevant timing window)
- Claim construction / dispositive motions (sets the probability of an injunction)
- Markman-type rulings (if present) that determine claim scope for infringement)
- Final judgment vs. stipulated dismissal (often indicates settlement)
Constraint: A complete litigation timeline (order dates and outcomes) cannot be stated without the docket’s specific entry record.
Did the case end in settlement, consent judgment, or dismissal?
Answer: The litigation record for this docket type is typically resolved by settlement that governs any authorized generic launch dates and may include stipulated dismissals with or without licensing terms.
What settlements usually include
- A stipulated dismissal of infringement claims
- A launch date schedule tied to patent expiry or agreed design-around dates
- A “no earlier than” clause for certain strengths or dosage forms
- Restrictions on labeling or marketing statements where relevant to approved indications
Constraint: Settlement outcome characterization for this specific docket requires the stipulation/order text and dates.
How strong is Purdue’s patent estate in this dispute?
Answer: The suit reflects Purdue’s selection of Orange Book patents deemed enforceable against Amneal’s ANDA product. Case strength in these litigations usually turns on:
- Claim construction of controlled-release or formulation terms
- Whether Amneal’s product infringes literal claim scope or under doctrine of equivalents
- Validity defenses (anticipation, obviousness, indefiniteness)
- Whether any asserted patents survive summary judgment
Typical strength indicators
- Multiple asserted patents increase leverage for settlement
- Narrow or “high-signal” claim limitations (release profile parameters, polymer characteristics, process steps) raise infringement risk for generics
- If Purdue’s asserted patents include one “core” patent that is hard to design around, settlement probability rises
Constraint: Patent-by-patent strength scoring cannot be performed without the complaint’s asserted claim set and the court’s rulings.
What is the Orange Book status and exclusivity timeline tied to this case?
Answer: Purdue’s asserted patents and FDA-listed exclusivities in the Orange Book create the exclusivity barrier that drives Hatch-Waxman litigation.
How the Orange Book shapes litigation outcomes
- Orange Book listings define which patents can be asserted in an ANDA case.
- FDA exclusivity (if applicable) can delay approval even if patent disputes narrow.
Commercial consequence
Generic market entry is governed by the earlier of:
- Patent expiry
- Court resolution enabling launch
- Settlement-defined entry permissions
- Expiration of exclusivity blocks (if they apply)
Constraint: The precise Orange Book listing entries (patent numbers, expiration dates, exclusivity type) cannot be listed for this docket from the case caption alone.
What Paragraph IV risks did Amneal face in 1:15-cv-01152-RGA-SR?
Answer: As the ANDA filer in a Paragraph IV framework, Amneal faced:
- Potential injunctions barring launch until resolution of infringement and validity
- Exposure to damages for pre-launch infringement if the court found claims infringed and valid
- Settlement pressure driven by 30-month stay leverage and injunction risk
Risk categories
- Injunction risk: Courts can grant immediate relief if infringement is likely and validity challenges fail.
- Design-around risk: If Amneal’s formulation/process does not avoid every required claim limitation, infringement may be found.
- Validity risk: If asserted patents survive dispositive validity challenges, the path to launch narrows.
Which generics/companies competed around Purdue during this period?
Answer: While this specific docket names Amneal as the defendant, Purdue’s opioid estate has historically been challenged by multiple generic applicants across multiple ANDAs. The relevant competitive set is determined by:
- Other ANDA filers with Paragraph IV certifications on the same Orange Book patents
- Separate district court cases with overlapping asserted patents
Constraint: A named competitor roster for this specific docket cannot be produced accurately without cross-referencing all related cases and the Orange Book patent list.
How does the case affect generic launch strategy for Amneal?
Answer: In this type of litigation, the case outcome sets whether Amneal:
- Launches at a specified date
- Launches only for certain strengths/forms
- Avoids infringement through labeling changes or formulation/process design around
- Waits for patent expiry
Typical launch gating
- “First strength first” schedules
- Shared distribution constraints
- FDA labeling timelines tied to the settlement and any court-ordered modifications
What manufacturing or formulation/IP barriers typically drive disputes like this?
Answer: For Purdue’s controlled-release opioid landscape, disputes typically hinge on:
- Release-rate and dissolution profiles tied to controlled-release engineering
- Polymer system selection and coating or matrix parameters
- Particle size, granulation method, and compression profiles
- Process parameters that affect drug layering or microscale release
Why these barriers matter
A generic can meet bioequivalence while still infringing if the claim scope captures structural/process equivalents or release-profile-defined features.
What is the litigation impact on Purdue’s revenue exposure?
Answer: This suit is a direct revenue-protection mechanism. The commercial exposure is the forecasted sales at risk if Amneal launches before patent expiry.
Business logic
- An ANDA litigation halts or delays entry while it is pending or while an injunction/settlement binds launch.
- Settlement timing converts a full-fleet entry threat into a controlled schedule.
Constraint: Revenue numbers for this docket cannot be quantified without product-specific sales data and agreement terms.
Key Takeaways
- Case type: Hatch-Waxman patent litigation in the District of Delaware (1:15-cv-01152-RGA-SR) brought by Purdue Pharma L.P. against Amneal Pharmaceuticals LLC.
- Core issue: Whether Amneal’s ANDA product infringes Purdue’s Orange Book-listed patents asserted under a Paragraph IV certification.
- Commercial consequence: The litigation governs whether and when Amneal can market a generic opioid product, commonly via settlement-defined launch permissions and patent-related carve-outs.
- Decision nodes: Court rulings on claim scope, infringement, and validity (and/or any stipulated settlement dismissal) determine entry timing more than technical similarity alone.
FAQs
1) What does “1:15-cv-01152-RGA-SR” indicate?
It is the District of Delaware case number with the assigned district judge (RGA) and magistrate (SR).
2) What does a Paragraph IV certification mean in an ANDA case?
It means the ANDA applicant asserts that the Orange Book patents cited by the reference listed drug are not infringed, invalid, or unenforceable.
3) How do these cases typically change generic launch timing?
They can trigger a statutory stay (where applicable) and often end in settlement schedules that set a permitted launch date.
4) Do formulation changes always avoid infringement?
Not always. If the generic still meets claim limitations (including release-profile or structural/process-defined limitations), changes may not avoid infringement.
5) Does an ANDA settlement require court findings of patent validity?
Not necessarily. Many settlements resolve the dispute without an adjudication on the merits via dismissal and agreed launch terms.
References (APA)
- Purdue Pharma L.P. v. Amneal Pharmaceuticals LLC, No. 1:15-cv-01152-RGA-SR (D. Del.).
